By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is that Pfizer's 6.6% yield is unsustainable due to the looming patent cliffs for Eliquis and Vyndaqel in 2028, which will lead to a significant revenue loss with no named blockbuster replacements. The high payout ratio and reliance on debt to fund the dividend raise concerns about future cash flow and potential dividend cuts.
Risk: The $8B+ annual revenue loss from Eliquis and Vyndaqel patent cliffs in 2028 with no named replacements.
Opportunity: None identified.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Pfizer is offering investors a huge 6.6% dividend yield.
The pharmaceutical giant isn't hitting on all cylinders, but dividend investors shouldn't abandon the company yet.
Pfizer (NYSE: PFE) is facing patent expirations for some of its biggest drugs. That's normal for a pharmaceutical company, but Pfizer doesn't appear to have any major new drugs to replace those losing patent protection. The big hit is likely to come from cardiology drugs Eliquis and Vyndaqel, which lose patent protections in 2028.
Those upcoming patent expirations are a major reason Wall Street is so downbeat on Pfizer's stock today. But that could be an opportunity for long-term dividend investors who don't mind taking on a little extra risk for a lot of extra yield.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
One of the big problems for pharmaceutical companies is that patent expirations happen on a set schedule, but drug development doesn't. So there can be a mismatch between the revenue lost during a patent expiration and the revenue from new drugs. It seems likely that Pfizer will face revenue headwinds through at least 2028 before it starts to grow its business again.
The story gets even more troubling when you consider that the payout ratio is well over 100%, sitting at 130% at the end of the first quarter of 2026. There's a good reason for investors to be worried about Pfizer's lofty 6.6% yield. However, dividends are paid out of cash flow, not earnings.
So Pfizer can use debt or cash on its balance sheet to support the dividend until its earnings improve. Notably, the cash dividend payout ratio, which compares the dividend to cash flow, is hovering around 100%. The financial impact of dividends appears on the cash flow statement, so this metric may be a better gauge of a company's true dividend-paying ability. While 100% is still high, it is clear that Pfizer can continue to comfortably support the dividend.
But it is important to consider that 6.6% yield from a broader perspective. The S&P 500 index (SNPINDEX: ^GSPC) is yielding just 1.1% right now. The average pharmaceutical stock's yield is 1.7%. And the average healthcare stock's yield is 1.7%. Pfizer's yield is six times that of the S&P 500 and over three times larger than that of other healthcare companies, including drug makers. The added risk doesn't seem quite as large as the yield difference.
Still, Pfizer's board of directors will make the final dividend decision. If it wants to keep paying a dividend and the company has the financial capacity to do it, as appears to be the case, then the dividend will continue to be paid. Management is telegraphing that this is the board's position, specifically stating that the company's goal is to support the dividend. It is unlikely that the CEO would say such a thing if the board were leaning toward a dividend cut.
From a long-term perspective, meanwhile, Pfizer is one of the most dominant healthcare companies on the planet. It has an over 100-year history of success behind it. It seems highly unlikely that the current headwinds, which are fairly normal in the drug sector, will permanently derail Pfizer.
For more aggressive dividend investors, this high-yield pharma giant's stock is probably worth the risk. The worst-case scenario is that the dividend is cut. But if history is any guide, the dividend won't be eliminated, and it will start growing again fairly quickly. That said, the last time the dividend was cut, the stock rose with the dividend when dividend increases resumed the quarter after the cut. If the dividend survives, meanwhile, you get a huge yield and the opportunity for price appreciation. In other words, downside risk seems fairly low if you are a long-term investor, while the upside could be very attractive.
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $477,813! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,320,088!
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 25, 2026. *
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The 100% cash payout ratio plus the 2028 patent losses on two major drugs leave the dividend more exposed than the article admits."
Pfizer's 6.6% yield looks tempting against the S&P 500's 1.1%, yet the article underplays the 2028 patent cliff on Eliquis and Vyndaqel, which together generate billions in annual revenue. With earnings payout at 130% and cash-flow coverage near 100%, any delay in new launches or higher R&D spend could force either deeper debt or a cut. The board's stated intent offers little protection once free cash flow turns negative, a scenario the sector has seen repeatedly at peers like Bristol-Myers. Long-term holders face reinvestment risk if the dividend is reset lower before growth resumes post-2028.
Pfizer has over $30B in cash and access to cheap debt, allowing it to bridge the gap until pipeline drugs reach the market without touching the dividend.
"Pfizer's dividend is mathematically safe but the stock faces 25-35% downside if the board cuts the payout by 40% to preserve balance-sheet flexibility through the 2028-2030 patent cliff trough."
The article conflates 'dividend safety' with 'stock safety'—two different things. Yes, PFE can service its 6.6% yield via cash flow at ~100% payout ratio, but that leaves zero margin for error. More critically: the article assumes patent cliffs are 'normal headwinds' that resolve, but Eliquis/Vyndaqel losses (2028) hit $8B+ in annual revenue with no named blockbuster replacements. The board's dividend commitment is theater—boards always say this before cuts. The real risk isn't dividend elimination; it's multi-year EPS compression forcing a 30-40% yield cut, which would crater the stock despite the dividend technically 'surviving.' The 6x S&P yield premium exists for a reason.
If Pfizer's pipeline delivers even one $2B+ peak-sales drug by 2029, the patent cliff narrative collapses and the stock re-rates sharply upward—the current pessimism may be overdone, making 6.6% yield genuinely cheap for a century-old pharma with pricing power.
"Pfizer's reliance on debt and cash reserves to sustain a 130% payout ratio is a structural red flag that signals potential dividend erosion or long-term capital impairment."
The article dangerously conflates 'cash flow' with 'dividend sustainability' while ignoring the capital-intensive nature of pharma. Pfizer (PFE) is currently in a 'value trap' cycle; relying on debt to fund a 130% earnings payout ratio is a classic late-stage defensive maneuver, not a strategy for growth. With Eliquis and Vyndaqel facing patent cliffs by 2028, the lack of a robust late-stage pipeline means Pfizer is essentially cannibalizing its balance sheet to satisfy yield-hungry retail investors. While the dividend might persist in the near term, the lack of organic R&D output suggests that capital allocation is prioritizing optics over long-term enterprise value, making the current 6.6% yield a compensation for eroding fundamentals rather than a bargain.
If Pfizer succeeds in its M&A strategy to acquire smaller biotech innovators, it could bridge the revenue gap, potentially turning the currently bloated payout ratio into a manageable cost of capital.
"Pfizer's 6.6% yield is not inherently safe; looming patent expirations and a high payout ratio could undermine dividend sustainability if cash flow weakens."
Pfizer offers a 6.6% yield, supported by a cash-payout ~100% and earnings payout around 130%, but the safety of that yield hinges on a robust free cash flow through 2028. The looming patent cliffs for Eliquis and Vyndaqel in 2028, plus a potentially weak immediate pipeline, raise the risk that revenue dips outpace any dividend growth. The high payout ratio suggests the dividend could be funded by debt or balance-sheet cash if earnings dip, and a board decision could shift if financial conditions deteriorate. Relative to a 1.1% S&P yield, the stock looks attractive only if you bet on a resilient pipeline and flexible financing.
The high current yield may be a mirage if cash flows falter; debt-funded dividends become riskier as interest costs rise and the patent cliff compresses earnings sooner than expected.
"M&A funded by debt would tighten, not loosen, the cash-flow noose before 2028."
Gemini's M&A bridge assumes acquisitions can offset the $8B cliff without quantifying dilution or integration costs. Those deals would likely require fresh debt at today's rates, directly inflating the interest burden ChatGPT flagged and accelerating the EPS compression Claude outlined. The result is a tighter timeline for any payout reset, not a delay to 2029.
"The cliff's timing, not its size, determines whether Pfizer can bridge it without a payout reset—and nobody's quantified the M&A execution window."
Grok's debt-funded M&A math is sound, but everyone's overlooking the timing mismatch. Patent cliffs hit 2028; Pfizer has 3.5 years to either launch internal pipelines or close deals. The real question isn't whether M&A works—it's whether Pfizer can execute *before* cash flow deteriorates enough to spike borrowing costs. That's a binary gate, not a gradual compression. If they move now, the math changes entirely.
"Regulatory hurdles and integration timelines render M&A an ineffective short-term solution for Pfizer's 2028 patent cliff."
Claude, your 'binary gate' theory ignores the regulatory reality: M&A in pharma isn't a plug-and-play fix. Integrating biotech assets takes years, and the current FTC scrutiny makes any significant acquisition a multi-year slog, not a quick pivot. Even if they sign a deal tomorrow, the EPS accretion won't hit until the cliff is already upon us. We are looking at a structural cash-flow crunch, not a tactical timing issue that can be solved by a single board-room maneuver.
"M&A alone won't rescue Pfizer before the 2028 cliff due to timing, dilution, and higher debt costs that raise the bar for debt-funded dividends."
Gemini's M&A bridge assumes deals can offset the 2028 cliff without quantifying dilution or higher financing costs. In pharma, regulatory delays and integration drag can push EPS accretion well beyond the cliff, while incremental debt raises interest expense and tightens covenants. Even if a deal signs, the timeline to meaningful cash-flow impact likely misses the window before borrowing costs rise further, making a debt-funded dividend riskier than the panelists suggest.
The panel consensus is that Pfizer's 6.6% yield is unsustainable due to the looming patent cliffs for Eliquis and Vyndaqel in 2028, which will lead to a significant revenue loss with no named blockbuster replacements. The high payout ratio and reliance on debt to fund the dividend raise concerns about future cash flow and potential dividend cuts.
None identified.
The $8B+ annual revenue loss from Eliquis and Vyndaqel patent cliffs in 2028 with no named replacements.